David Meek brings over 30 years of experience in the biopharmaceutical industry, where he has held key leadership positions across a range of publicly traded and private biotech companies. Most recently, Mr. Meek served as the Chief Executive Officer and a member of the Board of Directors at Mirati Therapeutics, Inc., a commercial-stage oncology biotech company. Mirati was acquired by Bristol Myers Squibb for $5.8 billion.
Prior to his tenure at Mirati, Mr. Meek was the CEO and a Board Member of FerGene, Inc., a private biotech company, from 2020 to 2021. From 2016 to 2020, he led Ipsen, a biopharmaceutical company headquartered in Paris, France, as its Chief Executive Officer and Board Member. Mr. Meek also held significant executive roles, including Executive Vice President and President of Oncology at Baxalta Inc., where he oversaw the oncology division through its acquisition by Shire. Earlier in his career, he served as Chief Commercial Officer at Endocyte, Inc., and held various executive positions at Novartis Pharmaceuticals and Novartis Oncology, following his initial roles at Johnson & Johnson and Janssen Pharmaceuticals.
Currently, Mr. Meek serves on the Boards of Directors for Cullinan Therapeutics Inc. and uniQure N.V., both publicly traded biotech companies. He is also a Board of Councilors member for the University of Southern California Mann School of Pharmacy and Pharmaceutical Sciences. His previous board roles include positions with the Pharmaceutical Research & Manufacturers of America (PhRMA), the European Federation of Pharmaceutical Industries & Associations, Fusion Pharmaceuticals Inc. (acquired by AstraZeneca), and Entasis Therapeutics Inc. (acquired by Innoviva, Inc.).
Mr. Meek holds a Bachelor of Arts degree from the University of Cincinnati.